03:35 PM EDT, 05/03/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target $7 to $21, 13.4x our 2024 EPS estimate (unchanged at $1.57; we keep our 2025 estimate at $1.97), above OMI's historical average to reflect the company's significant debt reduction in recent years, as well as expectations for near-term earnings growth momentum as part of the company's Vision 2028 Plan. Q1 adjusted EPS of $0.19 vs. $0.05 beat consensus expectations by $0.01. Sales of $2.6B rose 3.6% Y/Y, with modest negative effects from the Change Healthcare cyberattack during the quarter, offset by onboarding of new customers. Patient Direct segment sales (~24% of total) rose 5.0% Y/Y, while Products and Healthcare Services sales (~76% of total) rose 3.1% Y/Y. Adjusted EBITDA margin of 4.45% rose 3.2% vs. the 4.31% margin achieved in the prior-year quarter. OMI maintained its 2024 financial guidance and does not expect significant changes to its net debt ($1.9B). We expect leverage (net debt/EBITDA) around 3.3x by year end.